preview

Risk-Stratification Model Of A Risk-Stratification Of Myeloma

Satisfactory Essays
A risk-stratification model that depends on numerous independent molecular cytogenetic markers to evaluate disease aggressiveness is an important tool for both counseling and therapeutic decision-making. At the Mayo Clinic, using the Mayo stratification for myeloma and risk-adapted therapy (mSMART) classification, newly diagnosed myeloma is stratified into standard-, intermediate-, and high-risk disease. Patients with standard-risk myeloma have a median overall survival (OS) of 6–7 years while those with high-risk disease have a median OS of less than 2–3 years despite tandem autologous stem cell
Get Access